NASDAQ$SCYX
Scynexis Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended on June 30, 2022.
SCYNEXIS reported an increase in BREXAFEMME net product revenues from Q1 2022 to Q2 2022. The company has a projected cash runway into Q1 2024.
- BREXAFEMME net revenues were $1.3 million in Q2 2022, compared to $0.7 million in Q1 2022.
- SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand BREXAFEMME’s labelling to include the prevention of recurrent vulvovaginal candidiasis (RVVC); the FDA assigned a target PDUFA action date of November 30, 2022 for this additional indication.
- Enrollment has begun in two global Phase 3 trials: the MARIO study and the VANQUISH study.
- Based on a cash balance of $118.7 million at June 30, 2022, SCYNEXIS has a projected cash runway into Q1 2024.
Headline financials
Revenue & EPS history
Scynexis · Revenue · Quarterly
$1.32M
Revenue by segment
Scynexis · $22M total across 2 segments · Q4 2025
- License Agreement Revenue$20.6M+456.8%93.6%
- Product Revenue$1.4M—6.4%
Forward guidance
SCYNEXIS expects its cash runway will be into the first quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+0.4%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+2.0%
Avg return
30 days after
51%
27 / 53 earnings
Positive
+28.6%
Q1 2025
Best reaction
-38.9%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -10.0% | -19.2% | — | |
| Q4 2025 | +2.9% | +16.1% | +14.6% | |
| Q3 2025 | -5.6% | -4.8% | +4.0% | |
| Q2 2025 | -5.3% | -6.5% | +32.5% | |
| Q1 2025 | +28.6% | +21.9% | -5.3% | |
| Q4 2024 | -1.0% | -5.9% | +1.0% | |
| Q3 2024 | +0.0% | -3.0% | -9.8% | |
| Q2 2024 | -5.4% | -7.0% | -31.7% | |
| Q1 2024 | +1.6% | +10.6% | +20.3% | |
| Q4 2023 | +4.2% | +1.8% | +8.1% | |
| Q3 2023 | +0.3% | -5.0% | -2.1% | |
| Q2 2023 | -8.0% | -1.7% | +13.0% | |
| Q1 2023 | -3.8% | +1.0% | -4.5% | |
| Q4 2022 | +24.8% | +21.1% | +7.1% | |
| Q3 2022 | -14.7% | -12.5% | -5.4% | |
| Q2 2022 | +0.7% | -4.5% | +2.1% | |
| Q1 2022 | +10.7% | +14.4% | +4.3% | |
| Q4 2021 | -14.5% | -17.7% | -45.1% | |
| Q3 2021 | -5.9% | +20.5% | +27.7% | |
| Q2 2021 | -2.2% | -6.2% | -5.8% | |
| Q1 2021 | +11.5% | +21.1% | +5.6% | |
| Q4 2020 | +1.0% | +8.2% | -2.0% | |
| Q3 2020 | +13.3% | +15.4% | +34.0% | |
| Q2 2020 | -2.0% | -2.9% | -28.0% | |
| Q1 2020 | -0.3% | -7.3% | +1.2% | |
| Q4 2019 | -22.7% | -29.7% | +1.0% | |
| Q3 2019 | +3.5% | -1.3% | -34.9% | |
| Q2 2019 | +2.8% | +0.0% | +2.8% | |
| Q1 2019 | -2.6% | -7.8% | -24.0% | |
| Q4 2018 | +19.0% | +37.3% | +45.2% | |
| Q3 2018 | -2.3% | -8.4% | -41.2% | |
| Q2 2018 | -6.1% | -10.1% | -12.2% | |
| Q1 2018 | +8.5% | +7.6% | +52.5% | |
| Q4 2017 | +2.7% | +3.4% | -11.0% | |
| Q3 2017 | -9.3% | -9.3% | +12.9% | |
| Q2 2017 | +1.9% | -2.5% | +35.6% | |
| Q1 2017 | -38.9% | -36.2% | -37.4% | |
| Q4 2016 | +9.0% | +11.9% | -5.2% | |
| Q3 2016 | +4.5% | +18.5% | +14.3% | |
| Q2 2016 | -1.9% | +3.8% | +41.8% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +6.9% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | -4.3% | — | — | |
| Q4 2014 | +5.1% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q3 2014 | -0.8% | — | — | |
| Q2 2014 | +7.7% | — | — | |
| Q2 2013 | +7.7% | — | — | |
| Q1 2014 | +5.7% | — | — | |
| Q1 2013 | +5.7% | — | — | |
| Q4 2013 | +5.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro